Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by Wide Margin; Guides FY23

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of ($0.07), $4.58 worse than the analyst estimate of $4.51. Revenue for the quarter came in at $972.13 million versus the consensus estimate of $975.18 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2023 EPS of $16.90-$17.86, versus the consensus of $18.00. Jazz Pharmaceuticals sees FY2023 revenue of $3.675-3.875 billion, versus the consensus of $3.76 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
• MasTec to acquire The Superior Group for about $1.65 billion
• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'